Domov › Nevroblastom › Colorado
Klinične študije za Nevroblastom v Colorado
8 študij za Nevroblastom išče udeležence na lokacijah v Colorado.
Mesta v Colorado
Uradno besedilo študije (angleško)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Children's Hospital Colorado, Aurora
Vključevanje udeležencevFaza 3
Do 30 let · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
Vključevanje udeležencevFaza 1/2
6 Months – 25 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06395103Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Vključevanje udeležencevFaza 3
365 Days – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital Colorado, Aurora
Vključevanje udeležencevFaza 1/2
12 Months – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04851119NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Children's Hospital Colorado, Aurora
Vključevanje udeležencevFaza 2
Starost 1–31 · Vsi spoli · Posodobljeno 20. jul. 2026 · NCT06450041Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Children's Hospital Colorado, Aurora
Vključevanje udeležencevFaza 1/2
12 Months – 30 Years · Vsi spoli · Posodobljeno 19. maj 2026 · NCT04901702Neuroblastoma Biology Study
- Children Hospital of Colorado, Aurora
Vključevanje udeležencevOpazovalna študija
31 Days – 99 Years · Vsi spoli · Posodobljeno 23. mar. 2026 · NCT01587300A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's Hospital of Colorado, Aurora
Vključevanje udeležencevFaza 2
18 Months – 40 Years · Vsi spoli · Posodobljeno 12. avg. 2025 · NCT05135975Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.